Autologous T cells are gene-modified to express a third-generation anti-GD2 chimeric antigen receptor with CD28 and 4-1BB costimulatory domains and CD3ζ signaling. Binding to GD2 on tumor cells triggers T-cell activation and cytotoxic killing (perforin/granzyme, cytokines). An inducible caspase-9 safety switch enables pharmacologic elimination of the CAR T cells if severe toxicity occurs. Lymphodepleting chemotherapy facilitates CAR T expansion and persistence.